Clinical Trials | December 30, 2025
Biohaven reports Phase 2 depression trial results
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
The primary goal of the collaboration is joint research into trending and next-generation molecules
The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy
Lupin has bolstered its diabetes and obesity portfolios by securing an agreement for Bofanglutide, a GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals
The proceeds from the QIP will be used primarily to accelerate the nationwide expansion of the COCO stores of Davaindia nationwide
CLE, a common form of lupus erythematosus, primarily causes diverse skin lesions
Tolebrutinib had been provisionally approved in the United Arab Emirates in July 2025 for nrSPMS to slow disability accumulation independent of relapse activity
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
Subscribe To Our Newsletter & Stay Updated
